In one of its first acts as India's new leading drugmaker, Sun Pharmaceuticals announced the beginning of the end of Ranbaxy Laboratories by removing the company from the stock markets after trading has ended on April 1.
Harvard professor Doug Melton is having quite a week. His work on potential cell therapies for diabetes just fueled the launch of a well-funded biotech startup, and now he's signed up with AstraZeneca to help the drugmaker spotlight new treatments for the disease.
GE Healthcare announced that its diagnostic laboratory company, Clarient, will soon deploy Omnyx's proprietary software, as pathology pivots away from visual diagnosis and toward quantitative computer-based tools.
ImmunoGen has struck a $440 million antibody-drug conjugate licensing deal with Takeda, moving it a step closer to recovering from the body blow of last year's Phase III flop. The heavily backloaded deal was cheered by investors.
Calico, the Google-backed biotech with ambitions to decode the aging process, has aligned itself with California's QB3, a Bay Area brain trust, to further flesh out its R&D mission.
Sun Pharmaceuticals and Ranbaxy Laboratories have jumped the final hurdle in their merger with government approval of a sale of 7 of their branded drugs to fellow India drugmaker Emcure Pharmaceuticals.
Startup MHB Labs announced the receipt of $1.1 million in seed financing from Romulus Capital and other angel investors in support of its drug delivery technology for convenient administration of a commercially available but little-used medication that could have applications in the men's health space.
GlaxoSmithKline has reached out to the storied Cold Spring Harbor Laboratory to collaborate on a potential treatment for Type 2 diabetes and obesity, inking a multiyear R&D deal.
ZAI Lab of Shanghai has in-licensed from Bristol-Myers Squibb China rights to the Phase III liver cancer drug brivanib, an oral kinase inhibitor for oncology indications including hepatocellular carcinoma.
Japan's Astellas Pharma has filed with Japan's Pharmaceutical and Medical Devices Agency for approval of PCSK9 inhibitor evolocumab for high cholesterol under the Amgen Astellas BioPharma joint venture.